|4Mar 30, 5:16 PM ET

Maloberti Renaud Bertrand 4

4 · ENDRA Life Sciences Inc. · Filed Mar 30, 2022

Insider Transaction Report

Form 4
Period: 2022-03-28
Maloberti Renaud Bertrand
Chief Commercial Officer
Transactions
  • Award

    Stock Options

    2022-03-28+186,430186,430 total
    Exercise: $0.38Exp: 2032-03-28Common Stock (186,430 underlying)
Footnotes (1)
  • [F1]This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION